PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.05%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
19.02%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
656.99%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
656.99%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
405.55%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
333.33%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
333.33%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.13%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.61%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
101.50%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
70.07%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
276.85%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
276.85%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
20.73%
3Y revenue/share CAGR under 50% of AVGO's 62.33%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-97.07%
Negative 10Y OCF/share CAGR while AVGO stands at 580.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-97.07%
Negative 5Y OCF/share CAGR while AVGO is at 92.77%. Joel Greenblatt would question the firm’s operational model or cost structure.
-98.07%
Negative 3Y OCF/share CAGR while AVGO stands at 39.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
73.09%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
73.09%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-49.77%
Negative 3Y CAGR while AVGO is 16.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
698.62%
10Y equity/share CAGR at 75-90% of AVGO's 862.23%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
698.62%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
57.36%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.76%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
11.45%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.97%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
1.34%
Under 50% of AVGO's 5.15%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-33.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
2.88%
R&D dropping or stable vs. AVGO's 13.26%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-1.51%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.